SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Judy Garland — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJudy Garland
Date of birth1922-06-10
IdentifiersMRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127
Document date1955-07-20
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week review, eleven days after the supervised change to phenobarbital. [S]

History of Present Illness

Ms. Garland returns eleven days after a four-day admission to the addiction medicine service. Secobarbital was stopped on admission and phenobarbital was started and adjusted with withdrawal scoring; she had a mild tremor and poor sleep on the second night, no seizure and no confusion, and she was discharged on phenobarbital 32.4 mg three times daily. She has taken it as prescribed from the one-week supply and has taken no secobarbital. She was drowsy for the first three days at home, and that has passed. She sleeps four to five hours a night; her sleep diary shows that she lies awake for an hour after late rehearsals. She has kept to one 10 mg dextroamphetamine tablet each morning. She has taken sertraline 50 mg daily without side effects. Her mood is a little better. The dietitian could not see her yet because of a waiting list. [S]

ElementDetail
AdmissionFour days; mild tremor on one night; no seizure or delirium
Phenobarbital32.4 mg three times daily since discharge
SecobarbitalNone since admission
SleepFour to five hours; Insomnia Severity Index 18
Dextroamphetamine10 mg each morning
MoodPHQ-9 12; GAD-7 11

Review of Systems

SystemResultFinding
ConstitutionalNegativeDrowsiness after discharge has passed; no fever
NeurologicalNegativeNo tremor, unsteadiness or seizure-like episodes since discharge
PsychiatricPositiveMood low at times, better than at intake; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route1955-06-22 to 1955-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route1955-06-22 to 1955-07-20completedS
Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stopOne tablet each morning for two weeks, then stopOral route1955-07-20 to 1955-08-03completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-22 to 1955-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-29activeS
Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbitalOne tablet three times dailyOral route1955-07-06 to 1955-07-20completedS
Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a timePer the written taper schedule, in two or three divided dosesOral route1955-07-20activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route1955-06-22activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1955-07-20Body height151cmS
1955-07-20Body weight47.6kgS
1955-07-20Body mass index (BMI) [Ratio]20.9kg/m2S
1955-07-20Systolic blood pressure118mm[Hg]S
1955-07-20Diastolic blood pressure76mm[Hg]S
1955-07-20Heart rate82/minS
1955-07-20Respiratory rate14/minS
1955-07-20Body temperature36.6CelS
1955-07-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-07-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S
1955-07-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]11{score}S

Physical Exam

Vital signs recorded on 1955-07-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/76, pulse 82; weight 47.6 kg
NeurologicalNo tremor or nystagmus; finger-to-nose and gait normal
PsychiatricEngaged; no signs of sedation or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBarbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs)Every visitCompleted todayPhenobarbital 97.2 mg a day since discharge; no secobarbital; no withdrawal or sedation
ReferralSetting for barbiturate withdrawalBefore any reductionCompleted todayFour-day supervised admission completed without a seizure or delirium
Medication safetyTaper paceReductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performanceCompleted todayFirst step today, 97.2 to 81 mg a day (17%)
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly the hospital's and this clinic's prescriptions
LaboratoryUrine drug testing, explained as part of careAt the start, after the change to phenobarbital, and periodically during the taperCompleted todayBarbiturates and amphetamine, as prescribed; nothing else
Medication safetyLimited dispensing, locked storage and take-back of unused capsulesSeven days at first, then two weeks at a timeCompleted todayTwo-week supply from today; locked box
Medication safetyStimulant dose, extra doses, cravings, and blood pressure and pulseEvery visitCompleted today10 mg each morning, no extra doses; blood pressure 118/76, pulse 82; taper to 5 mg started
ExaminationElectrocardiogramBefore continuing a stimulantUp to dateNormal at intake
SurveyCBT for insomnia, sleep diary and Insomnia Severity IndexWeekly CBT-I sessions; sleep diary and index at each visitCompleted todayTwo CBT-I sessions; Insomnia Severity Index 18
Medication safetyNew hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine)Not recommended as a replacementNot indicatedNo new hypnotic
SurveyDepression (PHQ-9)At least monthly during acute treatmentCompleted todayPHQ-9 12, item 9 scored 0
SurveyAnxiety (GAD-7)With each PHQ-9 while anxiety is treatedCompleted todayGAD-7 11
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted today50 mg daily for three weeks; no side effects
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; safety plan reviewed; the 988 Suicide & Crisis Lifeline in her phone
Self-managementPsychotherapyWeeklyCompleted todayWeekly sessions continuing
ExaminationWeight, meals and disordered-eating screen, without a weight targetEvery visitCompleted todayWeight 47.6 kg, up 1.1 kg; two meals a day
ReferralDietitian visitWithin a month of intakeDeferredNot yet seen four weeks after intake because of a waiting list. No harm so far: weight is rising and she is eating more. Corrective action: the clinic booked a second dietitian with an earlier opening
Medication safetyContraception that phenobarbital does not weakenMedroxyprogesterone every 13 weeksUp to dateFirst injection at intake; next due in about nine weeks
Medication safetyNaloxoneReassess at every visit and whenever an opioid is prescribedNot indicatedNo opioids prescribed or used
Self-managementWork schedule and driving safetyWith each dose changeCompleted todayNo driving while drowsy; taper steps planned for weeks without major performances

Goal progress:

Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse phone check before each taper step. Ten-week review in six weeks. Weekly psychotherapy and CBT-I. Next scheduled visit 1955-08-31: ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and work. [S]